A5100615310- Hepatitis B Virus Studies
- Hepatitis C virus research
- Liver Disease Diagnosis and Treatment
- Systemic Lupus Erythematosus Research
- HIV/AIDS drug development and treatment
- Cytomegalovirus and herpesvirus research
- Hepatitis Viruses Studies and Epidemiology
- Complement system in diseases
- Advanced biosensing and bioanalysis techniques
- Social Acceptance of Renewable Energy
- RNA modifications and cancer
- Mosquito-borne diseases and control
- Viral Infections and Vectors
- HIV/AIDS Research and Interventions
- Immunotherapy and Immune Responses
- Mining and Resource Management
- Municipal Solid Waste Management
- HIV, Drug Use, Sexual Risk
- Balance, Gait, and Falls Prevention
- Viral gastroenteritis research and epidemiology
- Biosensors and Analytical Detection
- Cellular transport and secretion
- Vibrio bacteria research studies
- Coleoptera Taxonomy and Distribution
- Coronary Artery Anomalies
Southwest University
2025
Chinese Academy of Medical Sciences & Peking Union Medical College
2012-2024
Zhejiang Sci-Tech University
2022-2024
Guangzhou Eighth People's Hospital
2011-2023
Guangzhou Medical University
2013-2023
Fujian Medical University
2023
University of California, San Francisco
2020
Kunming University of Science and Technology
2019
Twelfth Guangzhou City People's Hospital
2016-2018
Hainan Center for Disease Control & Prevention
2017
Background: Studies tracking trends in HIV prevalence and risk behavior among men who have sex with (MSM) China are rare. We report on 3 consecutive cross-sectional surveys measuring the of HIV, other infectious diseases, related MSM Beijing 2004, 2005, 2006. Methods: applied respondent-driven sampling (RDS) to recruit for a structured face-to-face interview demographic characteristics risk-related behavior. Blood specimens were drawn syphilis, hepatitis B virus, C virus (HCV) testing....
<h3>Objective</h3> The investigation regarding the clinical significance of quantitative hepatitis B core antibody (anti-HBc) during chronic (CHB) treatment is limited. aim this study was to determine performance anti-HBc as a predictor for e antigen (HBeAg) seroconversion in HBeAg-positive CHB patients treated with peginterferon (Peg-IFN) or nucleos(t)ide analogues (NUCs), respectively. <h3>Design</h3> This retrospective cohort consisting 231 and 560 enrolled two phase IV, multicentre,...
There is no satisfactory way to identify patients who will maintain a response after discontinuation of nuleos(t)ide analogue therapy for chronic hepatitis B virus (HBV) infection. We investigated whether with negative results from tests HBV DNA and RNA (double negative) at the end treatment long-term treatment.We performed post-hoc analysis data 2-year multi-center randomized controlled trial, its extension trials, on 130 infection were positive HB e antigen (HBeAg-positive; mean age, 30.8...
The extensive application of building information modeling (BIM) technology has brought opportunities and challenges to safety risk management in the field prefabricated construction. It is great significance provide timely knowledge for decisions construction, display this visually. In response, based on ontology theory using Revit software, study we aimed establish a monitoring system construction buildings, which was verified through practical case. results revealed that, first, can be...
An optimization strategy based on the Roadmap concept is supposed to improve clinical outcomes of patients with suboptimal antiviral response. The aim this study was prove a multicenter, open-label, randomized, controlled study. In all, 606 hepatitis B e antigen (HBeAg)-positive, nucleos(t)ide-naive chronic were randomized Optimize or Mono group. Patients in group treated telbivudine for 24 weeks, after which those responders HBV DNA ≥300 copies/mL at week received plus adefovir until 104,...
Abstract Background Safe nucleos(t)ide analogue discontinuation in chronic hepatitis B (CHB) is an unmet need. We aimed to investigate whether combining virus (HBV) RNA and core–related antigen (HBcrAg) could perform satisfactorily predicting off-treatment outcomes. Methods The evaluation cohort included 127 e (HBeAg)–positive patients from a multicenter prospective trial who stopped telbivudine-based therapy after achieving HBeAg seroconversion HBV DNA &lt; 50 IU/mL for &gt; 48...
Shigella flexneri is a serious threat to global public health, and rapid detection method urgently needed. The CRISPR/Cas (clustered regularly interspaced short palindromic repeats/CRISPR-associated) system widely used in gene editing, therapy, vitro diagnosis. Here, we combined loop-mediated isothermal amplification (LAMP) CRISPR/Cas12a develop novel diagnostic test (CRISPR/Cas12a-E-LAMP) for the diagnosis of S. . CRISPR/Cas12a-E-LAMP protocol conducts LAMP reaction templates followed by...
BackgroundLimited studies have been done on chronic hepatitis B (CHB) patients defined according to the latest Asian-Pacific Association for Study of Liver guideline with liver histology by a large sample size. MethodsWe retrospectively evaluated histological characteristics cohort consecutive treatment-naive CHB persistent normal alanine aminotransferase (PNALT) or elevated ALT from May 2005 October 2011. Histological assessment was based Metavir scoring system, significant abnormality as...
This work investigated the modulatory effects of Pu-erh tea on gut microbiota in ameliorating hyperuricemia induced by circadian rhythm disruption.
Summary Liver biopsy is not routinely performed in treated chronic hepatitis B. stiffness measurement has been validated for noninvasive liver fibrosis assessment pretreatment B but assessed monitoring during antiviral therapy. was systemically monitored by Fibroscan ® every 6 months a cohort of patients with receiving therapy and compared biopsies at baseline week 104. A total 534 e antigen‐positive treatment‐naive telbivudine‐based qualified 104 were analyzed, 164 which had adequate paired...
Summary. The immune mechanism(s) that lead to hepatitis B‐related acute‐on‐chronic liver failure (HB‐ACLF) are poorly understood. Interleukin‐21 is a newly discovered cytokine involved in autoimmune and inflammatory diseases. Its potential role HB‐ACLF remains unknown. serum levels of 12 cytokines measured by cytometric bead arrays the frequency IL‐21‐secreting CD4 + T cells peripheral blood mononuclear (PBMC) intracellular staining were compared moderate chronic B (M‐CHB, n = 20), severe...
Summary Tenofovir disoproxil fumarate ( TDF ) has demonstrated long‐term efficacy and a high barrier to resistance in multiple chronic hepatitis B CHB populations outside of China. This study aimed evaluate the safety compared with adefovir dipivoxil ADV Chinese patients during 48 weeks treatment (ClinicalTrial.gov number, NCT01300234). A Phase 3, multicentred, randomized, double‐blind, controlled trial . The primary endpoint was proportion HBV DNA <400 copies/mL each group at Week 48,...
Abstract Background and aim Long-term treatment with tenofovir disoproxil fumarate (TDF) has demonstrated suppression of viral replication outside China. This study aims to assess efficacy, resistance safety TDF for up 240 weeks in Chinese patients chronic hepatitis B virus (HBV) infection. Methods Patients (HBeAg-positive or HBeAg-negative) who were randomised receive 300 mg adefovir dipivoxil (ADV) 10 once daily the 48-week double-blind phase ( N = 498) eligible enter open-label (TDF–TDF...
Abstract The existence of statistical associations between hepatitis B‐related acute‐on‐chronic liver failure and both B virus (HBV) genotype mutations in the basal core promoter (BCP) precore (PC) regions needs to be confirmed. A total 322 patients with a chronic HBV infection, including 77 failure, 109 hepatocellular carcinoma (HCC) 136 (CHB) were enrolled. presence BCP/PC determined by direct sequencing, frequencies compared three patient groups. Overall, 198/322 (61.5%) infected 124/322...
Abstract Background and Aim Daclatasvir plus asunaprevir has demonstrated efficacy safety in patients with chronic hepatitis C virus genotype 1b infection. This study focused on evaluating daclatasvir interferon (±ribavirin)‐ineligible or ‐intolerant Asian infection from mainland China, Korea, Taiwan. Methods Interferon received 60 mg tablets once daily 100 soft capsules twice for 24 weeks. The primary endpoint was sustained virologic response at post‐treatment week (SVR24). Results Of the...
The role of vitamin D in individuals with chronic hepatitis B (CHB) is unclear. We aimed to explore the association baseline level genetic determinants and week-104 treatment outcome CHB patients.Baseline serum 25-hydroxycholecalciferol (25(OH)D) levels polymorphism within GC, DHCR7, CYP2R1 were determined stored 560 patients who enrolled into a multicenter, randomized, controlled study completed 104 weeks telbivudine monotherapy or telbivudine-based optimized therapy. Virologic response was...